EU approval makes Novo Nordisk’s oral semaglutide the first and only oral GLP-1 RA to reduce cardiovascular death, heart attack and stroke
The hospital was recognised as a Winner (Medium) in the category of Best Academic Institution (Government/Private)
Designed as an “AI-as-a-Service” platform, VECURA aims to reduce the traditional therapeutic drug discovery timeline of 10–12 years to just a few hours.
Drug Hunter is already relied upon by researchers at more than 200 leading organizations, including Eli Lilly, Biogen, Merck KGaA, Isomorphic Labs, Deerfield Management
RN3161 is engineered to reduce fat while preserving lean mass, setting it apart from current treatment options
ABP-745 is a novel oral therapy with potential applications in cardiovascular and other inflammatory diseases
Dr. Brown brings extensive international experience in oncology and radiopharmaceutical development,
Late-breaking data presented at WCLC highlight significant and sustained improvements in overall survival, including more than doubling five-year survival rates compared to chemotherapy alone
Cagrilintide represents a novel approach to obesity management
Subscribe To Our Newsletter & Stay Updated
